Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8646385 | 0.92 | GAA (0.49) | GAANPSR1HSD17B10KDM4EMEN1 | |
| SCHEMBL15601402 | 0.90 | GAA (0.50) | GAANPSR1HSD17B10KDM4EMEN1 | |
| SCHEMBL21241110 | 0.90 | SMN1; SMN2 (0.51) | GAANPSR1HSD17B10KDM4EMEN1 | |
| SCHEMBL6967258 | 0.87 | GAA (0.48) | GAANPSR1HSD17B10KDM4EMAPK1 | |
| SCHEMBL5356914 | 0.83 | SMN1; SMN2 (0.55) | GAANPSR1HSD17B10KDM4EMEN1 | |
| SCHEMBL1573002 | 0.83 | SMN1; SMN2 (0.55) | GAANPSR1HSD17B10KDM4EMEN1 | |
| SCHEMBL14356222 | 0.82 | KMT2A (0.53) | GAAHSD17B10MEN1RECQLKMT2A | |
| SCHEMBL6494581 | 0.82 | GAA (0.66) | GAANPSR1HSD17B10KDM4EMEN1 | |
| SCHEMBL25226906 | 0.81 | GAA (0.53) | GAANPSR1HSD17B10KDM4EMEN1 | |
| SCHEMBL25824251 | 0.81 | GAA (0.53) | GAANPSR1HSD17B10KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10682419-B2 | Prodrugs of peptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20180147291-A1 | PRODRUGS OF PEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2018-05-31 | — | — | US | disclosed |
| US-9878047-B2 | Prodrugs of peptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20160263234-A1 | PRODRUGS OF PEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2016-09-15 | — | — | US | disclosed |
| US-9315542-B2 | Prodrugs of peptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9309283-B2 | Prodrugs of peptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| EP-2869820-A2 | PRODRUGS OF PEPTIDE EPOXY KETONE PROTEASE INHIBITORS | Onyx Therapeutics, Inc. (US) | 2015-05-13 | — | — | EP | disclosed |
| US-20140105921-A1 | Prodrugs of Peptide Epoxy Ketone Protease Inhibitors | ONYX THERAPEUTICS, INC. | 2014-04-17 | — | — | US | disclosed |
| US-20140100168-A1 | Prodrugs of Peptide Epoxy Ketone Protease Inhibitors | ONYX THERAPEUTICS, INC. | 2014-04-10 | — | — | US | disclosed |
| US-20140100154-A1 | Prodrugs of Peptide Epoxy Ketone Protease Inhibitors | ONYX THERAPEUTICS, INC. (US) | 2014-04-10 | — | — | US | disclosed |
| US-20050124605-A1 | Novel benzo-fused heterocycles as endothelin antagonisits | ACTELION PHARMACEUTICALS LTD. | 2005-06-09 | — | — | US | disclosed |
| US-6586357-B1 | Stereospecific catalysts; enantioselective reduction; transition metal complexes | CHEMI S.P.A. (IT) | 2003-07-01 | — | — | US | disclosed |
| WO-2003013545-A1 | NOVEL BENZO-FUSED HETEROCYCLES AS ENDOTHELIN ANTAGONISITS | ACTELION PHARMACEUTICALS LTD (CH) | 2003-02-20 | — | — | WO | disclosed |
| US-6297387-B1 | AND THEIR USE AS CHIRAL CATALYSTS IN STEREOCONTROLLED REACTIONS, SUCH AS DIASTEREO- AND ENANTIOSELECTIVE REDUCTION REACTIONS, | ITALFARMACO SUD S.P.A. (IT) | 2001-10-02 | — | — | US | disclosed |
| US-6133191-A | Heteroaromatic diphosphines as chiral ligands | ITALFARMACO SUD S.P.A. (IT) | 2000-10-17 | — | — | US | disclosed |
| US-6077958-A | Heteroaromatic diphosphines as chiral ligands | ITALFARMACO SUD S.P.A. (IT) | 2000-06-20 | — | — | US | disclosed |
| EP-0770085-B1 | HETEROAROMATIC DIPHOSPHINES AS CHIRAL LIGANDS | CHEMI SPA (IT) | 1999-09-22 | — | — | EP | disclosed |
| US-5907045-A | Heteroaromatic diphosphines as chiral ligands | ITALFARMACO SUD S.P.A. (IT) | 1999-05-25 | — | — | US | disclosed |
| EP-0770085-A1 | HETEROAROMATIC DIPHOSPHINES AS CHIRAL LIGANDS | ITALFARMACO SUD S.p.A. (IT) | 1997-05-02 | — | — | EP | disclosed |
| WO-1996001831-A1 | HETEROAROMATIC DIPHOSPHINES AS CHIRAL LIGANDS | ITALFARMACO SUD S.P.A. (IT) | 1996-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140105921-A1 | Prodrugs of Peptide Epoxy Ketone Protease Inhibitors | PREP, VIP, PEPD | GAA 565/4885NPSR1 663/4885HSD17B10 493/4885 |
| US-20050124605-A1 | Novel benzo-fused heterocycles as endothelin antagonisits | EDNRA, EDNRB, ECE1 | GAA 2736/4885NPSR1 30/4885HSD17B10 2545/4885 |
| US-20140100168-A1 | Prodrugs of Peptide Epoxy Ketone Protease Inhibitors | PREP, VIP, PEPD | GAA 565/4885NPSR1 663/4885HSD17B10 493/4885 |
| US-20160263234-A1 | PRODRUGS OF PEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, VIP, PEPD | GAA 565/4885NPSR1 663/4885HSD17B10 493/4885 |
| US-20180147291-A1 | PRODRUGS OF PEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, VIP, PEPD | GAA 565/4885NPSR1 663/4885HSD17B10 493/4885 |
| US-20140100154-A1 | Prodrugs of Peptide Epoxy Ketone Protease Inhibitors | PREP, VIP, PEPD | GAA 565/4885NPSR1 663/4885HSD17B10 493/4885 |
| US-10682419-B2 | Prodrugs of peptide epoxy ketone protease inhibitors | PREP, VIP, PEPD | GAA 565/4885NPSR1 663/4885HSD17B10 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.